Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2004 1
2005 1
2006 1
2007 4
2008 1
2009 3
2010 1
2011 1
2012 3
2014 4
2015 5
2016 9
2017 3
2018 8
2019 12
2020 15
2021 18
2022 11
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Fanconi anemia, complementation group S"
Page 1
Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D. Baretta Z, et al. Medicine (Baltimore). 2016 Oct;95(40):e4975. doi: 10.1097/MD.0000000000004975. Medicine (Baltimore). 2016. PMID: 27749552 Free PMC article. Review.
RESULTS: BRCA1 mutation carriers have worse OS than BRCA-negative/sporadic cases (hazard ratio, HR 1.30, 95% CI: 1.11-1.52) and worse BCSS than sporadic/BRCA-negative cases among patients with stage I-III breast cancer (HR 1.45, 95% CI: 1.01-2.07). ...Among Ashkenazi Jewis …
RESULTS: BRCA1 mutation carriers have worse OS than BRCA-negative/sporadic cases (hazard ratio, HR 1.30, 95% CI: 1.11-1.52) and worse …
BRCA Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies.
Lee YC, Lee YL, Li CY. Lee YC, et al. Medicina (Kaunas). 2021 Aug 30;57(9):905. doi: 10.3390/medicina57090905. Medicina (Kaunas). 2021. PMID: 34577828 Free PMC article. Review.
Background and Objectives:BRCA1 and BRCA2 are genes located in different chromosomes that are disproportionately associated with hereditary breast and ovarian cancer syndrome. ...Conclusion: The meta-analysis results can provide clinicians and relevant families with …
Background and Objectives:BRCA1 and BRCA2 are genes located in different chromosomes that are disproportionately associated wi …
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM. Konstantinopoulos PA, et al. J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27. J Clin Oncol. 2020. PMID: 31986064 Free PMC article.
RECOMMENDATIONS: All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes. In women who do not carry a germline pathogenic or likely pathogenic BRCA1/2 variant, somatic t …
RECOMMENDATIONS: All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2 and other ovaria …
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. Tew WP, et al. J Clin Oncol. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924. Epub 2020 Aug 13. J Clin Oncol. 2020. PMID: 32790492 Free PMC article.
For patients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2 (g/sBRCA2) genes should be treated with olaparib. ...
For patients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2 (g/sBRCA2) genes s …
Risk-reducing mastectomy for the prevention of primary breast cancer.
Carbine NE, Lostumbo L, Wallace J, Ko H. Carbine NE, et al. Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD002748. doi: 10.1002/14651858.CD002748.pub4. Cochrane Database Syst Rev. 2018. PMID: 29620792 Free PMC article. Review.
The studies presented data on 15,077 women with a wide range of risk factors for breast cancer, who underwent RRM.Twenty-one BRRM studies looking at the incidence of breast cancer or disease-specific mortality, or both, reported reductions after BRRM, particularly for those women …
The studies presented data on 15,077 women with a wide range of risk factors for breast cancer, who underwent RRM.Twenty-one BRRM studies lo …
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, Kohlmann WK, Kurian AW, Laronga C, Lynce F, Norquist BS, Plichta JK, Rodriguez P, Shah PD, Tischkowitz M, Wood M, Yadav S, Yao K, Robson ME. Bedrosian I, et al. J Clin Oncol. 2024 Feb 10;42(5):584-604. doi: 10.1200/JCO.23.02225. Epub 2024 Jan 4. J Clin Oncol. 2024. PMID: 38175972
All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralatera …
All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless …
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P, Sacco E. Marino F, et al. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):655-664. doi: 10.1038/s41391-022-00609-3. Epub 2022 Nov 24. Prostate Cancer Prostatic Dis. 2023. PMID: 36434163 Review.
DISCUSSION: Emerging data show that germline mutations in homologous recombination genes (BRCA1/2, ATM, CHECK2), in mismatch repair genes (MLH1, MLH2, MSH6), and other additional genes are associated with the development and aggressiveness of PCa. ...
DISCUSSION: Emerging data show that germline mutations in homologous recombination genes (BRCA1/2, ATM, CHECK2), in mismatch r …
Risk factors for developing both primary breast and primary ovarian cancer: A systematic review.
Ferris JS, Morgan DA, Tseng AS, Terry MB, Ottman R, Hur C, Wright JD, Genkinger JM. Ferris JS, et al. Crit Rev Oncol Hematol. 2023 Oct;190:104081. doi: 10.1016/j.critrevonc.2023.104081. Epub 2023 Aug 2. Crit Rev Oncol Hematol. 2023. PMID: 37541535 Review.
Studies observed a lower risk of BROV for Black versus White women, alcohol consumption, radiotherapy and hormone therapy, BRCA2 versus BRCA1, and ER/PR positive versus negative breast tumors, and a higher risk with family history of breast/ovarian cancer, triple negative …
Studies observed a lower risk of BROV for Black versus White women, alcohol consumption, radiotherapy and hormone therapy, BRCA2 versus B …
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM, Chandran E, Floudas CS, Choo-Wosoba H, Butera G, Roselli M, Gulley JL, Karzai F. Iannantuono GM, et al. Cancer Treat Rev. 2023 Nov;120:102623. doi: 10.1016/j.ctrv.2023.102623. Epub 2023 Sep 9. Cancer Treat Rev. 2023. PMID: 37716332 Free article. Review.
PARPi monotherapy improved radiographic PFS and OS over SoC in mCRPC patients with alterations in BRCA1 or BRCA2 genes but not in those with alterations in the ATM gene. ...CONCLUSION: The efficacy of PARPi is not uniform across mCRPC patients with alterations in DN …
PARPi monotherapy improved radiographic PFS and OS over SoC in mCRPC patients with alterations in BRCA1 or BRCA2 genes but not …
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, Huang J, Zhang Z. Zhu Y, et al. Oncotarget. 2016 Oct 25;7(43):70113-70127. doi: 10.18632/oncotarget.12158. Oncotarget. 2016. PMID: 27659521 Free PMC article. Review.
However, this did not translate into poor BCSS (BRCA1: HR = 1.14, 95% CI, 0.81 to 1.16, p = 0.448; BRCA2: HR = 1.16; 95% CI 0.82 to 1.66, p = 0.401) or EFS (BRCA1: HR = 1.10, 95% CI, 0.86 to 1.41, p = 0.438; BRCA2: HR= 1.09; 95% CI 0.81 to 1.47, p = 0.558). ...BR …
However, this did not translate into poor BCSS (BRCA1: HR = 1.14, 95% CI, 0.81 to 1.16, p = 0.448; BRCA2: HR = 1.16; 95% CI 0.82 to 1 …
97 results